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Protein sequencingThe development of nicotinic acetylcholine receptor (nAChR) agonists, particularly those that discriminate
between neuronal nAChR subtypes, holds promise as potential therapeutic agents for many neurological
diseases and disorders. To this end, we photoafﬁnity labeled human α4β2 and rat α4β4 nAChRs afﬁnity-
puriﬁed from stably transfected HEK-293 cells, with the agonists [125I]epibatidine and 5[125I]A-85380. Our
results show that both agonists photoincorporated into the β4 subunit with little or no labeling of the β2
and α4 subunits respectively. [125I]epibatidine labeling in the β4 subunit was mapped to two overlapping
proteolytic fragments that begin at β4V102 and contain Loop E (β4I109–P120) of the agonist binding site.
We were unable to identify labeled amino acid(s) in Loop E by protein sequencing, but we were able to
demonstrate that β4Q117 in Loop E is the principal site of [125I]epibatidine labeling. This was
accomplished by substituting residues in the β2 subunit with the β4 homologs and ﬁnding [125I]
epibatidine labeling in β4 and β2F119Q subunits with little, if any, labeling in α4, β2, or β2S113R
subunits. Finally, functional studies established that the β2F119/β4Q117 position is an important
determinant of the receptor subtype-selectivity of the agonist 5I-A-85380, affecting both binding afﬁnity
and channel activation.© 2009 Elsevier B.V. All rights reserved.1. IntroductionNeuronal nicotinic acetylcholine receptors (nAChR) comprise a
diverse group of cation-selective ligand-gated ion channels that are
widely distributed in neuronal and non-neuronal cells [1]. Within the
nervous system, nAChRs inﬂuence a variety of neuronal functions by
mediating the action of the endogenous neurotransmitter acetylcho-
line (ACh) and modulating the release of ACh and a panel of other
neurotransmitters [2]. Therefore, drugs that target neuronal nAChRs
have therapeutic potential in many pathophysiological conditions
including Alzheimer's disease and nicotine addiction [3]. The neuronal
nAChRs are pentameric membrane proteins formed by the assembly
of ﬁve nAChR subunits (e.g. homomeric α7 and heteromeric α4β2
nAChRs). The agonist binding sites (ABS) of nAChRs are located within
the N-terminal extracellular domain at the interface of adjacent
subunits and different nAChR subunit combinations form ABS with
distinct physical and pharmacological properties [4,5]. This diversity
of neuronal nAChR subtypes, which is typical for many brain regions,
makes it necessary to develop subtype-selective ligands to pharma-
cologically target a speciﬁc nAChR subtype without invoking sidefax: +1 806 743 2744.
lanton).
ll rights reserved.effects associated with binding at other nAChRs. The high degree of
sequence homology among nAChR subunits (38–68%) allows the use
of common structural templates such as the 4 Å structure of Torpedo
nAChR [6] and the X-ray structure of the acetylcholine binding protein
(AChBP; [7,8]) to study the ABS of neuronal nAChRs. But, to develop
subtype-selective ligands, it is necessary to develop more reﬁned
models that reﬂect the subtle structural differences among the ABS of
different neuronal nAChR subtypes.
In heteromeric neuronal nAChRs, the principal components of
the ABS (amino acids in Loops A–C) are carried by α subunits and
the complementary components (amino acids in Loops D–F) are
carried by the β2 or β4 subunit. Amino acid residues that contribute
to the ABS from Loops A–C are conserved among α subunits except
α5 which do not form an ABS [9]. In the complementary component
of the ABS, amino acid residues in Loops D, E and F, except the
tryptophan residue in Loop D, are not conserved among Torpedo
(muscle-type) γ and δ and neuronal β2 and β4 nAChR subunits.
Regardless of the α subunit subtype, the presence of either the β2
or β4 subunit inﬂuences the pharmacological properties of the ABS.
Epibatidine and its analogue, iodoepibatidine, bind with high afﬁnity
(~pM) to heteromeric neuronal nAChRs and with much lower afﬁnity
to homomeric neuronal and muscle nAChRs [3]. [3H]epibatidine (and
[125I]epibatidine) bind with higher afﬁnity to β2- compared to β4-
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~22 fold; α4β2/α4β4, ~3 fold; [10,11]. 5I-A-85380, a more recently
introduced agonist, shows very high discrimination between α4β2
andα4β4 receptors. It is much less potent at inhibiting binding of [3H]
epibatidine to theα4β4 receptor (IC50 24 nM) than theα4β2 receptor
(IC50 0.06 nM; [10]).
While the structural determinants that are responsible for these
pharmacological differences are not completely understood, amino
acid residues within Loop E are implicated in conferring agonist
binding selectivity between β2- and β4-containing nAChRs. Substitu-
tion of amino acids β4-(106–120) with β2-(104–120) confers β2-like
agonist binding properties [12]. Moreover, azidoepibatidine, a photo-
reactive analogue of epibatidine, labels M116 within Loop E (as well as
C195 within Loop C) of Aplysia AChBP [13].
In this report, we extended these studies by employing [125I]
epibatidine and 5[125I]A-85380 as photoafﬁnity probes of the agonist
binding domain of α4β2 and α4β4 nAChRs. Starting with nAChRs
afﬁnity-puriﬁed from stably transfected HEK-293 cells, our data show
that both [125I]epibatidine and 5[125I]A-85380 selectively photoincor-
porate into the β4 subunit (with little or no labeling in β2 and α4
subunits respectively) and for [125I]epibatidine speciﬁc (agonist inhibi-
table) labelingmapped to Loop E (β4I109–P120) of the complementary
component of the agonist binding site. We were unable to directly
determine the sites of labeling in the β4 subunit by protein sequencing.
However, we introduced point mutations in Loop E at β2S113 and
β2F119 (equivalent to M116 in AChBP) to the corresponding residues in
the β4 subunit (designated hereafter β2S113R and β2F119Q, respec-
tively). For wild-type andmutant nAChRs transiently expressed in HEK-
293 cells, we found labeling in the β4 and β2F119Q subunits, indicating
that β4Q117 is the principal site of [125I]epibatidine labeling in theα4β4
nAChR. Furthermore, when we tested the effect of these mutations on
agonist binding and channel activation, we found that β2F119 but not
β2S113playa signiﬁcant role in determining thepharmacological proﬁle
of the ABS of the α4β2 nAChR.
2. Material and methods
2.1. Materials
[125I]epibatidine and 5[125I]A-85380 (2200 Ci/mmol) were
obtained from Perkin Elmer Life Sciences, Inc. (Boston, MA) and
stored in 95% ethanol at 4 °C. Acetylcholine chloride (ACh),
carbamylcholine chloride (Carb), and bromoacetylcholine bromide
were from Sigma-Aldrich (St. Louis, MO). 5-iodo-A-85380 dihy-
drochloride (5I-A-85380) was from Tocris, Ellisville, MO. Glutamyl
endopeptidase Glu-C (V8 protease) was from MP Biochemicals and
trypsin (TPCK-treated) from Worthington. Peptide-N-Glycosidase F
(PNGase F; 5 U/μL), endo-β-N-acetylglycosaminidase (Endo H; 3 mU/
μl), and protease inhibitor cocktail set III were from Calbiochem
(LaJolla, CA. Sodium cholate and CHAPS were from USB Corporation
(Cleveland, OH). Afﬁ-Gel 10 was from Bio Rad (Hercules, CA).
2.2. Constructs, transient transfection and stable cell line
These techniques have been published [14–16]. Human α4 and β2
constructs were kindly provided by Dr. Jon M. Lindstrom (University
of Pennsylvania) (α4 accession number NM000744, β2 accession
number NM 000748). Subunit cDNAs were transferred to pcDNA3
(Invitrogen, San Diego CA) for expression. Mutations weremade using
the QuikChange kit (Stratagene, La Jolla CA), and all mutated subunits
were sequenced over the full length of the subunit to conﬁrm that
only the desired mutation had been produced. HEK 293 cells for
transient transfectionwere plated in 150mm tissue culture dishes and
transfected when at about 75% conﬂuence. Transient transfections
were performed using Effectene according to the manufacturer's
instructions (Qiagen, Valencia CA), with amixture of equal amounts ofα4 and β2 cDNA. Cells were washed with culture medium 24 h after
transfection and harvested 2 to 3 days later.
The HEK 293 cell line that stably expresses hα4β2 nAChRs (HEK-
hα4β2 hereafter) was prepared by growing the transfected cells in the
presence of G418 (450 μg/mL) and immunoselectionwith mAb 270 as
described [16]. HEK293 cells stably expressing ratα4β4 nAChRs (HEK-
α4β4 hereafter) were kindly provided by Drs. Yingxian Xiao and
Kenneth J. Kellar (GeorgetownUniversity; [10]). HEK-hα4β2 andHEK-
rα4β4 cells were grown at 37 °C in a humidiﬁed incubator at 5% CO2,
in 150 mm tissue culture dishes and were maintained in DMEM/
Ham's F-12 (Mediatech, Inc.), supplemented with 10% fetal bovine
serum,100 U/mL penicillin G,100 μg/mL streptomycin and 450 μg/mL
geneticin (G418) as a selection agent.
2.3. Membrane preparation and afﬁnity puriﬁcation
For membrane preparation, transiently transfected HEK 293, HEK-
hα4β2 and HEK-rα4β4 cells were homogenized in vesicle dialysis
buffer (VDB: 100 mM NaCl, 0.1 mM EDTA, 0.02% NaN3, 10 mM MOPS,
pH 7.5) in the presence of 0.2 μL/mL protease inhibitor cocktail set III
(Calbiochem). Membrane fractions were isolated by centrifugation
(39,000 g for 1 h) then resuspended in VDB containing 0.2 μL/mL
protease inhibitor cocktail III and stored at −80 °C. For afﬁnity
puriﬁcation, HEK-hα4β2 and HEK-rα4β4 cell membranes in VDB
containing 0.2 μL/mL protease inhibitor cocktail III (1 mg/mL protein)
were solubilized with 1% CHAPS, centrifuged (91,500 g for 1 h) to
pellet insoluble material, and then dialyzed for 5 h against 1% cholate.
The hα4β2 and rα4β4 nAChRs (typically from ~600 dishes; ~2 g HEK-
293 cell membrane protein) were afﬁnity-puriﬁed on a bromoace-
tylcholine bromide-derivatized Afﬁ-Gel 10 column and reconstituted
into asolectin/total lipid extract from porcine brain (Avanti Polar
Lipids) lipid vesicles as previously described [17]. The purity of hα4β2
and rα4β4 nAChRs was N50% as estimated by densiometric
quantiﬁcation of Coomassie Blue stained gels and by [3H]nicotine
binding (~4 nmol binding sites/mg of protein). Densiometric analysis
of stained gels containing α4β2 and α4β4 AChRs was also consistent
with a pentameric subunit stoichiometry of (α4)2(β2/β4)3 [17].
2.4. [125I]Epibatidine and 5[125I]A-85380 photolabeling
nAChR containing HEK cell membranes (~500 μg) and afﬁnity-
puriﬁed hα4β2 and rα4β4 nAChR membranes (~30 μg) were
incubated for 1 h with ~1 nM [125I]epibatidine or 5[125I]A-85380
(2200 Ci/mmol) in the absence or presence of 100 μM nicotine (or
100 nM epibatidine) then irradiated in glass text tubes, for 30 or
15 min respectively with a 254 nm hand-held UV lamp (Spectroline
EN-280L). The labeled membranes were then pelleted by centrifuga-
tion (39,000 g for 1 h), resuspended in electrophoresis sample buffer
(12.5 mM Tris–HCL, 2% SDS, 8% sucrose, 1% glycerol, 0.01% bromo-
phenol blue, pH 6.8), and resolved on 8% polyacrylamide/0.33
bisacrylamide gels [18]. After staining with Coomassie Blue R-250
(0.25% (w/v) in 45% methanol, 10% acetic acid, 45% H2O) and
destaining to visualize bands, gels were dried and exposed to Kodak
X-OMAT LS ﬁlmwith an intensifying screen at−80 °C (overnight to 4
week exposure). The bands corresponding to the β4 subunit and a
lower molecular weight fragment of β4 (β4′) were excised from
stained 8% polyacrylamide gels, soaked in overlay buffer (5% sucrose,
125 mM Tris–HCl, 0.1% SDS, pH 6.8) for 30 min, transferred to 15%
polyacrylamide mapping gels and digested in-gel with 10 μg V8
protease [19]. After electrophoresis, the mapping gels were processed
for autoradiography as described above.
2.5. Isolation and sequencing of [125I]epibatidine-labeled peptides
[125I]Epibatidine-labeled β4 subunit was isolated from a prepara-
tive scale labeling (~1mg afﬁnity-puriﬁed rα4β4 nAChR at 0.3mg/mL
Fig. 1. Photoincorporation of [125I]epibatidine (panel A) and 5[125I]A-85380 (panel B)
into α4β4 nAChRs. ~0.3 mg of afﬁnity-puriﬁed rα4β4 nAChRs were co-equilibrated for
1 h with 6 μCi [125I]epibatidine or 5[125I]A-85380 (~1 nM) in the absence (− lanes) and
presence (+ lanes) of 100 μM nicotine or 100 nM epibatidine respectively, then
irradiated in glass test tubes at 254 nm for 30 or 15 min respectively. For [125I]
epibatidine labeling samples, in a parallel experiment, ~0.1 mg from the same batch of
afﬁnity-puriﬁed rα4β4 nAChRs were equilibrated for 1 h with 10 μCi [125I]TID (0.4 μM)
then irradiated at 365 nm for 7 min. The polypeptides were resolved by SDS-PAGE.
Shown are autoradiographs of 8% acrylamide gels containing α4β4 nAChRs photo-
labeled with [125I]TID (panel A, lane 1; 2 day exposure), [125I]epibatidine (panel A, lanes
2 and 3; 1 week exposure), and 5[125I]A-85380 (panel B, lanes 1 and 2; 1 week
exposure). The electrophoretic mobility of α4 and β4 subunits and the proteolytic
fragment β4′ are indicated.
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digestion with V8 protease. Based on the autoradiograph of the
mapping gel, labeled bands were excised and the polypeptides were
retrieved by passive diffusion into 25 mL of elution buffer (0.1 M
NH4HCO3, 0.1% (w/v) SDS, 1% β-mercaptoethanol, pH 7.8) and
concentrated in Centriprep-10 and Centricon-3 concentrators (10/
3 kDa cutoff, Amicon) to a ﬁnal volume of ~150 μl.
For sequence analysis, the eluted peptides were further puriﬁed by
reversed-phaseHPLConaShimadzu LC-10AbinaryHPLC system, usinga
Brownlee Aquapore C4 column and a nonlinear elution gradient
described in the legend for Fig. 2. Fractions were collected every
2.5 min at a ﬂow rate of 0.2 mL/min and 125I cpm associated with each
fraction was determined by γ-counting. Peak 125I cpm containing
fractions were loaded onto PVDF ﬁlters using Prosorb® Sample
Preparation Cartridges (Applied Biosystems#401959) as recommended
by themanufacturer and sequencedonanAppliedBiosystemsPROCISE™
492 protein sequencer conﬁgured to utilize 1/6 of each cycle of Edman
Degradation for amino acid detection and the other 5/6 for 125I cpm
counting.
For digestion with PNGase F and Endo H, eluted peptides were
acetone precipitated (N85% acetone at −20 °C overnight) to remove
SDS, resuspended in 100 μL of Tris buffer (15 mM Tris, 0.1% SDS; pH
8.3) and incubated at room temperature for 2 days with 25 U of
PNGase or 15 mU of Endo H. The digests were then fractionated on
small pore (16.5%T, 6%C) Tricine SDS-PAGE gels [20]. After electro-
phoresis, Tricine gels were processed for autoradiography as described
above for 8% gels.
2.6. [3H]Epibatidine saturation and competition binding assays
Saturation binding of [3H]epibatidine (45.1 Ci/mmol; Perkin Elmer
Life Sciences) and the effect of 5I-A-85380 on [3H]epibatidine binding
to hα4β2, rα4β4, hα4β2F119Q and hα4β2S113R nAChR HEK-293 cell
membranes were determined using a centrifugation assay. For
saturation [3H]epibatidine binding, membranes at 0.33 mg protein/
mL VDB were incubated for 5 h at room temperature with increasing
concentrations of [3H]epibatidine (ﬁnal concentrations 2–60 nM). For
competition binding, membranes at 0.25 mg protein/mL were
incubated for 5 h at room temperature with [3H]epibatidine (5 nM),
in the absence or the presence of increasing concentrations of 5I-A-
85380 (ﬁnal concentrations 0.1 nM–10 μM). For both saturation and
competition binding, bound and free [3H]epibatidine were separated
by centrifugation (39,000 g for 1 h) then quantiﬁed by liquid
scintillation counting. For saturation [3H]epibatidine binding, total,
nonspeciﬁc, and speciﬁc 3H cpmwere converted to fmol of bound [3H]
epibatidine/mg of protein, and free 3H cpmwas converted to nM [3H]
epibatidine. For competition binding, bound [3H]epibatidine was
normalized as a percentage of total binding in the absence of 5I-A-
85380. Non-speciﬁc binding was determined in the presence of
150 μM epibatidine. Curve ﬁtting and parameter estimations (includ-
ing calculation of standard deviation) were performed using Graph
Pad Prism v5.0 software (San Diego, CA).
2.7. Oocyte expression and electrophysiological recordings
Voltage clamp electrophysiological studies were made of receptors
expressed in Xenopus oocytes [15,21]. cRNA was synthesized by
linearizing the plasmid with Xho1, followed by cRNA synthesis using
mMessage mMachine T7 kit (Ambion, Austin TX). The cRNA was
dissolved in RNAase-free water, and 10 to 12 ng (based on the OD at
260 nm) in avolume of 18nLwas injected into each oocyte. The subunits
were injected at a 1:8 ratio (α4:β2). Oocyteswere voltage clampedwith
a two-electrode clamp (Warner Instruments, Hamden CT). The bath
solution contained (mM)NaCl, 96; KCl, 2;MgCl2,1; BaCl2,1.8; HEPES,10;
pH adjusted to 7.5 with NaOH, and recordings were made at room
temperature (approximately 18–21 °C). Analogue data were ﬁltered at20 Hz with a Bessel low pass ﬁlter and digitized at 50 ms intervals with
using pClamp (Molecular Dynamics, Mountain View CA). Data were
subsequently analyzed using pClamp, Excel (Microsoft, Redmond WA)
and SigmaPlot (Systat Software, San Jose CA). Concentration–response
curves were ﬁt with the equation Y(X)=Ymax {Xn/(Xn+EC50n )}, where
Ymax is the maximal response, X is the concentration of agonist, EC50 is
the concentration producing a half-maximal response and n is the Hill
coefﬁcient. ACh was prepared as a 1 M stock solution and 5I-A-85380
was prepared at 50 mM in ion exchange-puriﬁed distilled water and
stored in aliquots at −20 °C. All solutions applied were made freshly
from stock on the day of an experiment.
3. Results
3.1. [125I]Epibatidine and 5[125I]A-85380 labeling of α4β4 and α4β2
nAChRs
Photoafﬁnity labeling studies were carried out with human α4β2
and rat α4β4 neuronal nAChRs afﬁnity-puriﬁed from stably trans-
fected HEK-293 cells. Following a 1 h equilibration with 1 nM [125I]
epibatidine or 5[125I]A-85380, nAChR samples (30 μg in 500 μL VDB)
were irradiated for 30 or 15 min (at 254 nm) respectively and the
pattern of incorporation assessed by SDS-PAGE followed by auto-
radiography. As seen in the autoradiographs of 8% acrylamide gels
(Fig. 1), for α4β4 nAChRs both [125I]epibatidine (Fig. 1A) and 5[125I]A-
85380 (Fig. 1B) incorporated selectively into the β4 subunit, including
a lower molecular weight band subsequently identiﬁed as a
proteolytic fragment of the β4 subunit (β4′), with no apparent
labeling of theα4 subunit. The speciﬁcity of labeling was addressed by
co-application of 100 μM nicotine (Fig. 1, +lanes), which signiﬁcantly
Fig. 2. Mapping the sites of [125I]epibatidine (panel A) and 5[125I]A-85380 (panel B)
photoincorporation in the β4 subunit and β4′ subunit fragment. The bands
corresponding to the β4 subunit and the β4′ subunit fragment were isolated from an
8% SDS-PAGE gel containing rα4β4 nAChRs labeled with [125I]epibatidine/5[125I]A-
85380 in the absence (− lanes) and presence (pre-equilibrated; + lanes) of 100 nM
nicotine or 100 nM epibatidine (e.g. Fig. 1A lanes 2 and 3) and subjected to in-gel
digestion with V8 protease. Panel A, ([125I]epibatidine) following electrophoresis, the
mapping gel was exposed to X-ray ﬁlmwith an intensifying screen for 4 weeks. Panel B,
(5[125I]A-85380) following electrophoresis, the mapping gel was exposed to X-ray ﬁlm
with an intensifying screen for 3 weeks. Panels C and D, reversed-phase HPLC
puriﬁcation of β4′V8-6.4 and β4′V8-14.1 fragments isolated from a larger scale
preparative [125I]epibatidine labeling in the absence of agonist. A nonlinear elution
gradient (dotted line) of solvent B (0.05% TFA in 60% acetonitrile/40% isopropanol) in
solvent A (0.08% TFA in water) at a ﬂow rate of 0.2 mL/min was employed. The elution
of peptides was monitored by the absorbance at 210 nm (solid line). Fractions were
collected every 2.5 min and 125I cpm associated with each fraction (●) was determined
by γ-counting. HPLC fractions 19–20 for β4′V8-6.4 (C) and fractions 21–22 for β4′V8-
14.1 (D) were pooled for automated Edman degradation (protein sequencing).
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reduction) in both the β4 subunit and the β4′ subunit fragment as
determined byγ-counting of excised gel bands. In subsequent labeling
experiments, a 15min preincubation ofα4β4 nAChRmembranes withFig. 3. Amino acid sequence alignment of Loop E from different nAChRs. The approximat
glycosylation are in bold and italicized, and amino acids in the β4 subunit identiﬁed by proeither 100 μM nicotine or 100 nM epibatidine (Fig. 1B, +lane) prior to
the addition of radiolabeled agonist resulted in a complete elimination
of labeling.
In contrast to α4β4 nAChRs, for α4β2 nAChRs very little if any
photoincorporation is apparent in either the α4 or β2 subunit for
either [125I]epibatidine or 5[125I]A-85380 (Supplementary Fig. S1).
This result was rather surprising given the pM binding afﬁnity of
epibatidine and 5I-A-85380 for α4β2 nAChRs and the high degree of
sequence conservation between the β2 and β4 subunits (64%; [22])
and immediately suggests that labeling differences betweenα4β2 and
α4β4 nAChRs primarily reﬂect differences in the photoreactivity of a
limited number of amino acid residues.
The bands corresponding to the β4 subunit and β4′ fragment were
next isolated from 8% gels and digested in-gel with V8 protease. [125I]
epibatidine and 5[125I]A-85380 photoincorporation was detected in
two subunit fragments with apparent molecular masses of 6.4 kDa
(β4V8-6.4; β4′V8-6.4) and 14.1 kDa (β4V8-14.1; β4′V8-14.1;Fig. 2). In
each, addition of 100 nM epibatidine during nAChR labeling
eliminated incorporation in each subunit fragment (Fig. 2, +lanes)
consistent with labeling that is restricted to the agonist binding
domain.
3.2. Mapping the sites of [125I]epibatidine labeling in the α4β4 nAChR
While the cost of 5[125I]A-85380 (Perkin Elmer) made preparative
scale labeling experiments prohibitively expensive, to identify [125I]
epibatidine-labeled fragments, β4V8-6.4, β4V8-14.1 (from β4 and
β4′) were isolated from a preparative scale labeling (1 mg α4β4
nAChR; 13 nM [125I]epibatidine) and further puriﬁed by reversed-
phase HPLC (Fig. 2C and D). HPLC fractions containing peak 125I cpm
were pooled and subjected to automated Edman degradation (10
sequencing cycles). The primary peptide detected for both β4V8-6.4
and β4V8-14.1 fragments began at β4V102 [residue and pmol amount
detected in each sequencing cycle for β4V8-6.4 are V(30)/S(5)/V
(20)/Y(10)/T(6.5)/N(11)/V(10)/I(11)/V(9)/R(5) and for β4V8-14
are V(12.6)/S(2.6)/V(2.3)/Y(1.4)/T(1.2)/N(1.9)/V(1.8)/I(1.1)/V(2)/
R(0.4)]. As shown in Fig. 3 (the ﬁrst ten amino acids detected by
protein sequencing are underlined) generation of these two peptides
results from V8 protease cleavage at β4E101. Based on the apparent
molecular mass of each fragment (6.4 and 14 kDa), each of these two
fragments extends well beyond β4V102 and contains the amino acid
sequence of Loop E (β4-I109–P120) of the complementary component
of the agonist binding sites. While the primary peptide detected in
sequencing of β4V8-6.4 and β4V8-14.1 began at β4V102, it is possible
that the radioactivity ([125I]epibatidine labeling) is associated with a
peptide sequence that was present at much lower abundance and
therefore was not detected during sequencing. To further conﬁrm the
association between the radioactivity (i.e. [125I]epibatidine labeling)
and the proteolytic fragments containing Loop E (β4V- and β4V8–
14.1), we took advantage of the fact that β4V102 is located 12 and 40
amino acids before two potential sites for N-glycosylation at β4N113
and β4N141, respectively (bold and italicized in Fig. 3). We therefore
examined the effects of Endo H, which hydrolyzes asparagine-linked
oligomannose but not complex oligosaccharides, and PNGase F, whiche limits of Loop E are indicated, key residues are in bold, potential sites of N-linked
tein sequencing of βV8-14.1 and βV8-6.4 (Fig. 2) are underlined.
Fig. 4. The effect of deglycosylation on the electrophoretic mobility of β4V8-6.4 and
β4V8-14.1 fragments. [125I]Epibatidine-labeled β4V8-6.4 and β4V8-14.1 fragments (e.g.
Fig. 2) were digested at room temperature for 2 days with 25 U of PNGase or 15 mU of
Endo H. Then untreated (control) and enzyme treated (+ lanes) fragments were
resolved on a 1 mm thick 16.5% Tricine SDS-PAGE gel. Following electrophoresis, the
tricine gel was stained, destained, dried and exposed to X-ray ﬁlm with an intensifying
screen for 2 weeks. The electrophoretic mobility of prestained low-range molecular
weight standards (Life Technologies, Inc.) are indicated on the left.
1991A.K. Hamouda et al. / Biochimica et Biophysica Acta 1788 (2009) 1987–1995hydrolyzes asparagine-linked high mannose as well as complex
oligosaccharides, on the electrophoretic mobility of β4/β4′V8-6.4
(V102–E131) and β4/β4′V8-14.1 (V102–E175; Fig. 4). The autoradio-Fig. 5. Panels A–C, [3H]epibatidine binding to WT α4β2 (A), α4β2S113R (B), and α4β2F1
temperature with increasing concentrations of [3H]epibatidine (ﬁnal concentrations 0.23–
determined by liquid scintillation counting. Bound 3H cpmwas converted to fmol bound [3H
epibatidine. Non-speciﬁc binding (○) was determined in the presence of 150 μMepibatidine.
performed using Graph Pad Prism v5.0 software (San Diego, CA). For WT α4β2 nAChRs the
Kd=410±105 pM, Bmax=1.53±0.77 pmol/mg;α4β2F119Q nAChRs, Kd=711±64 pM, Bma
the effect of 5I-A-85380 (0.1 nM–10 μM) on [3H]epibatidine binding to hα4β2 (■), rα4β4 (◆
fraction was determined by scintillation counting and IC50 values calculated by curve ﬁt ana
rα4β4, 2.23±0.13 μM).graphic bands for Endo H- and PNGase F-treated β4V8-6.4 migrated
with an apparent molecular mass of 4 kDa (2.4 kDa shift) consistent
with the removal of a oligomannose (simple sugar) at β4N113. The
bands for Endo H- and PNGase F-treated β4V8-14.1 migrated with an
apparent molecular mass of 7.4 kDa (6.7 kDa shift) consistent with the
removal of two simple sugar moieties (~3.3 kDa each) at β4N113 and
β4N141. While these results are consistent with the site of [125I]
epibatidine photoincorporation residing in Loop E of the agonist
binding site, alternative explanations are possible. For example, V8
cleavage at β4E47 could generate fragments of 5.4 kDa (with
glycosylation ~7 kDa) and 10 kDa (~14 kDa) that include glycosylation
at β4N68 and β4N113 and labeling within Loop D (e.g. W55, K57).
However, a peptide sequence beginning at β4D48 was not detected in
sequencing of β4V8-6.4 and β4V8-14.1 material and the apparent
molecular mass and deglycosylation shift of β4V8-6.4 are not
consistent with the results presented in Fig. 4, leaving [125I]
epibatidine photoincorporation within Loop E as the simplest
explanation of the data.
When the [125I]epibatidine-labeled β4V8-6.4 fragment was sub-
jected to amino acid sequencing on a conﬁguration that allows
quantiﬁcation of 125I cpm release associated with each cycle of Edman
degradation, the release proﬁle reﬂected a wash out of 125I cpm from
the sequencing ﬁlter (Supplementary Fig. S2). This result suggests that
the labeling of one or more amino acids was not stable during amino
acid sequencing. To further test this, a Loop E-containing peptide was
isolated from [125I]epibatidine-labeled Torpedo γ subunit and sub-
jected to amino acid sequencing under the same conditions
(Supplementary Fig. S3). The 125I cpm proﬁle was similar to that for
β4V8-6.4 establishing that the UV-induced [125I]epibatidine amino19Q (C) nAChRs. Membranes at 0.33 mg protein/mL were incubated for 5 h at room
11.4 nM). Bound and free 3H were separated by centrifugation and the 3H cpm was
]epibatidine/mg protein (total,□;speciﬁc,■) and free 3H cpmwas converted to nM [3H]
Curve ﬁtting, parameter estimations (including calculation of standard deviations) were
[3H]epibatidine Kd=613±86 pM, Bmax=2.75±0.84 pmol/mg; α4β2S113R nAChRs,
x=4.92±0.12 pmol/mg. Panel D, structures of iodoepibatidine and 5I-A-85380. Panel E,
), hα4β2F119Q (●) and hα4β2S113R (□) nAChRmembranes was examined. The bound
lysis (hα4β2, 11.43±0.89; hα4β2S113R, 11.18±0.68 nM; hα4β2F119Q, 40.0±1.9 nM;
Fig. 6. [125I]epibatidine photolabeling of WT and mutant α4β2 nAChRs. Membranes
isolated fromHEK 293 cells transiently expressingα4β2F119Q,α4β2S113R orWTα4β2
receptors (~1.5 pmol [3H]epibatidine binding sites per condition) were pre-incubated
for 30minwith 100 nM epibatidine (+ lanes) or not (− lanes) and then incubatedwith
5 nM [125I]epibatidine for 1 h. Samples were then irradiated for 30 min at 254 nm and
the polypeptides were resolved on a 8% polyacrylamide gel. Shown is the autoradio-
graph of an 8% gel (3 week exposure with an intensifying screen). The electrophoretic
mobility of α4 and β2 subunits are indicated on the left.
Fig. 7. Pharmacological properties ofmutatedβ2 subunits expressed in Xenopus oocytes.
Wild-type and mutated β2 subunits were expressed with α4 in Xenopus oocytes. Panel
A shows responses of oocytes to 1 mM ACh (solid traces) or 10 μM 5I-A-85380 (dashed
traces). Each pair of traces is from a single oocyte, and the responses have been
normalized to the response to ACh (actual amplitudes of the ACh responses are: wild-
type−0.8 μA, β2 S113R−3.3 μA, F119Q−0.03 μA). Note that for wild-type and S113R
subunits the response to maximal 5I-A-85380 is larger than that to maximal ACh,
whereas this is not true for F119Q. Panel B shows the concentration–response curve for
ACh, normalized to the response at 1 mM ACh. The EC50 values are similar (see Results).
Panel C shows the concentration–response curve for 5I-A-85380, again normalized to
the response of that oocyte to 1 mM ACh. The β2 F119Q shows both a reduced maximal
response and a larger EC50 than wild-type or the S113R mutation (see Results).
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limiting our ability to directly determine the site of [125I]epibatidine
photolabeling in Loop E through direct sequencing of labeled peptide.
As detailed in the following sections we therefore explored other
means by which to identify the site(s) of [125I]epibatidine photo-
incorporation in the α4β4 AChR.
3.3. Effect of β2S113R and β2F119Q mutations on receptor expression
and epibatidine and 5I-A-85380 binding afﬁnity
As stated previously, [125I]epibatidine/5[125I]A-85380 labeling of
the β4 subunit (forα4β4 nAChRs) and the absence of labeling inα4β2
nAChRs is rather surprising given the pM binding afﬁnity of
epibatidine and 5I-A-85380 for α4β2 nAChRs and the high degree
of sequence conservation between the β2 and β4 subunits (64%; [22])
and immediately suggest that labeling differences between α4β2 and
α4β4 nAChRs primarily reﬂects differences in the photoreactivity of a
limited number of amino acid residues within Loop E of the agonist
binding domain. Amino acids within Loop E have been previously
implicated in the differences of binding afﬁnities between α−γ and
α−δ ABS of the mouse nAChR [23] and between β2- and β4-
containing nAChRs [12]. Amino acid sequence alignment of β2 and β4
nAChR subunits (Fig. 3) and the fact that azidoepibatidine labeled
M116 within Loop E of the Aplysia AChBP [13] suggest that β4Q117
(equivalent to M116 in AChBP) and possibly β4R111 (this non
conserved residue is located on the same face of β-strand as
β4Q117) are likely targets for [125I]epibatidine and 5[125I]A-85380
labeling and the corresponding residues in the β2 subunit (β2F119
and β2S113) may be important selectivity determinants of β2-
containing receptors. To test this, we constructed hα4β2 receptors
containing point mutations at β2S113 and β2F119, in which the
residue at each position was substituted to the corresponding residue
in the rat β4 subunit (β2F119Q and β2S113R, respectively, hereafter).
When α4β2F119Q and α4β2S113R receptors were transiently
expressed in HEK 293 cells, they displayed similar expression levels
(~2–4 pmol [3H]epibatidine binding sites/mg protein) and [3H]
epibatidine binding afﬁnities (400–700 pM) to those of the wild-
type (WT) hα4β2 (Fig. 5A–C). Competition binding experiments (Fig.5E) further established that the α4β2 selective agonist 5I-A-85380
([10]; Fig. 2D) displaced [3H]epibatidine binding to α4β2 and
α4β2S113R nAChRs with identical potency (IC50 11.43±0.89 and
11.18±0.68 nM respectively), but with ~4- and 200-fold reduced
potency for hα4β2F119Q and rα4β4 nAChRs (IC50 40.0±1.9 nM and
2.23±0.13 μM respectively).
1993A.K. Hamouda et al. / Biochimica et Biophysica Acta 1788 (2009) 1987–19953.4. Effect of β2S113R and β2F119Q mutations on [125I]epibatidine
photolabeling
Membranes fromHEK 293 cells transiently expressingα4β2F119Q,
α4β2S113R or WT α4β2 receptors were photolabeled with [125I]
epibatidine under equivalent conditions (that is approximately the
same amount, 1.5 pmol, of receptor was present in each labeling
sample; Fig. 6). While the level of [125I]epibatidine labeling is low (3
week exposure), not surprising given the small amount of nAChR
(1.5 pmol) present in each sample, we did not detect any 125I cpm
associated with the α4 subunit, consistent with previous labeling
results with afﬁnity-puriﬁed α4β2 and α4β4 nAChRs. There is
however clear [125I]epibatidine photoincorporation into the β2F119Q
subunit but not the β2S113R or WT β2 subunit. Furthermore,
preincubation of α4β2 nAChR membranes with 100 nM epibatidine
prior to the addition of [125I]epibatidine completely eliminated
labeling in the β2F119Q subunit (Fig. 6, + lanes). These results are
consistent with the absence of labeling in the β2 subunit (for WT
α4β2 nAChRs) resulting from a lack of [125I]epibatidine (and likely 5
[125I]A-85380) photoreactivity with β2F119 and with β4Q117 in Loop
E being the principal site of [125I]epibatidine labeling in the α4β4
nAChR.
3.5. Effect of β2S113R and β2F119Q mutations on α4β2 nAChR activation
The pharmacological properties of receptors containing mutated
β2 subunits were examined by expressing receptors in Xenopus
oocytes. Subunit cRNAs were injected at a ratio of 1:8:α4:β2, which
results in a preferred subunit stoichiometry of (α4)2(β2)3 [24,25].
Oocytes expressing receptors with α4 paired with any of the β2
constructs respond to applications of ACh (Fig. 7A). Activation by ACh
is similar for receptors containing wild-type β2, β2S113R or β2F119Q
subunits (EC50 values respectively 3.7±0.3 μM (5), 8.8±2.1 μM (5)
and 6.7±0.7 μM (5); mean±SE for ﬁts to data for (N) oocytes; see
Fig. 7B).
We then tested the agonist 5I-A-85380. Previous physiological
studies of 5I-A-85380 have found that this drug is a potent and
efﬁcacious agonist at nicotinic (α4)2(β2)3 receptors [25], with an EC50
about 10 nM and a maximal response larger than that for ACh itself.
Our data for receptors containing wild-type β2 are similar (Fig. 7C).
For receptors containing wild-type β2, the maximal response to 5I-A-
85380 is 1.6±0.1 (5) times the response to 1 mM ACh and the EC50 is
23±2 nM (5). Activation of receptors containing the β2S113R subunit
is indistinguishable from wild-type (Fig. 7C; maximal response ratio
1.7±0.1 (7) and EC50 30±7 nM (7)). However, the presence of the
β2F119Q mutation both reduces the maximal relative response and
shifts the EC50 to a higher concentration of 5I-A-85380 (Fig. 7C;
maximal response ratio 1.0±0.0 (5) and EC50 338±77 nM (5)). Both
the maximal response ratio and the EC50 differ signiﬁcantly from
values for wild-type or β2S113R subunits (Pb0.02 for response ratio
and Pb0.001 for EC50, ANOVA with Bonferroni correction).
4. Discussion
4.1. Photoincorporation of [125I]epibatidine and 5[125I]A-85380 into the
agonist binding domain of nAChRs
In this report we introduced the agonists [125I]epibatidine and 5
[125I]A-85380 as photoafﬁnity probes of the agonist binding domain of
neuronal nAChRs. It has been well established that iodoepibatidine
and 5I-A-85380 bind with high afﬁnity (0.062–24 nM; [10]) to α4β2
and α4β4 nAChRs. We show here with α4β2 and α4β4 nAChRs
afﬁnity-puriﬁed from stably transfected HEK-293 cells, that irradia-
tion at 254 nm results in selective photoincorporation of [125I]
epibatidine and 5[125I]A-85380 into the β4 subunit with little to no
labeling of the α4 and β2 subunits. We further show that this labelingis highly speciﬁc and is localized to the agonist binding domain in that
preincubation with nicotine or epibatidine completely eliminates
labeling for either radiolabeled agonist (Fig. 1B; Fig. 2). Selective
photoincorporation of [125I]epibatidine and 5[125I]A-85380 into the β4
subunit (no labeling of the α4 and β2 subunits) contrasts with the
selective labeling of theα4 subunit (α4β2 AChRs) by azidoepibatidine
[13]. On the other hand, azidoepibatidine labeled residues on both the
principal (Y195, Loop C) and complementary (M116, Loop E) faces of
the AChBP [13] and therefore labeling at the subunit level alone is not
a predictor of AChR-subtype ligand selectivity. Moreover, the effect
that the iodo group (Fig. 5D)may exert on the orientation of the ligand
in the binding site and/or the photochemistry must also be
considered as well as additional factors such as the photoreactivities
of individual amino acids.
Site(s) of [125I]epibatidine labeling in the β4 subunit were next
mapped to two overlapping proteolytic fragments that begin at β4V102
and contain the amino acid sequence of Loop E (β4I109–P120) of the
complementary component of the agonist binding site. We were not
able to identify amino acids in Loop E that reacted with [125I]epibatidine
by protein sequencing as the labeling was not stable under the acidic
conditions of automated Edman degradation. We were however able to
provide further conﬁrmation that the radioactivity ([125I]epibatidine)
was associatedwith Loop E, that is there are one ormore sites of labeling
contained within Loop E, by: 1) demonstrating that the electrophoretic
mobility of labeled bands which contain Loop E, β4/β4′V8-6.4 (V102-
E131) andβ4/β4′V8-14.1 (V102-E175),were shifted by endoglycosidase
treatment in amanner consistentwith the removal of asparagine-linked
simple sugar moieties at β4N141 and/or β4N113 (Fig. 4); 2) [125I]
epibatidine labeling within the Torpedo (muscle-type) nAChR also
mapped to a proteolytic fragment containing Loop E of the γ-subunit
(Supplementary Fig. S3).
Several lines of evidence led us to then examine β4Q117 and
β4R111 in Loop E as likely site(s) of [125I]epibatidine labeling: 1)
labeling in the β4 subunit (for α4β4 nAChRs) and the lack of labeling
in the β2 subunit (for α4β2 nAChRs) cannot be explained by a lack of
binding given the pM binding afﬁnity of iodoepibatidine for α4β2 and
α4β4 nAChRs [10]; 2) the high degree of sequence conservation
between β2 and β4 subunits (64%; [22]) and in particular the amino
acid sequence alignment of Loop E of β2 and β4 subunits (Fig. 3),
immediately suggests that labeling differences between α4β2 and
α4β4 nAChRs primarily reﬂect differences in the photoreactivity of a
limited number of amino acid residues within Loop E (i.e. positions
that differ in β2/β4: β4I109, β4R111, β4S112, β4N113, and β4Q117); 3)
that azidoepibatidine labeled M116 (equivalent to β4Q117) within
Loop E of the Aplysia AChBP [13] and β4R111 is located on the same
face of the β-sheet as β4Q117. To then (indirectly) determine whether
or not β4Q117 and/or β4R111 are site(s) of [125I]epibatidine labeling
in α4β4 nAChRs, we constructed hα4β2 receptors containing point
mutations at β2S113 and β2F119, inwhich the residue at each position
was substituted to the corresponding residue in the rat β4 subunit
(β2F119Q and β2S113R, respectively, hereafter). We found that
replacement of β2F119, but not β2S113, with the corresponding β4
residues is sufﬁcient to result in [125I]epibatidine photoincorporation
similar to that seen in WT α4β4 receptors (Fig. 6). These results
indicate that the lack of [125I]epibatidine labeling of the WT β2
subunit results from a lack of photoreactivity towards β2F119 and
provides indirect evidence that β4Q117 is the major site of [125I]
epibatidine photolabeling in α4β4 nAChRs. While additional studies
are needed to further map the sites of 5[125I]A-85380 with the β4
subunit, that the receptor subtype labeling was identical to that of
[125I]epibatidine and that labeling in the β4 subunit mapped to the
same proteolytic fragments β4/β4′V8-6.4 and β4/β4′V8-14.1 (Fig.
2B), strongly suggest that β4Q117 in Loop E is also the principal site of
5[125I]A-85380 labeling. These results are again also consistent with
labeling of M116 (equivalent to β4Q117) in the AChBP by azidoepi-
batidine [13]. The photoreactive azido group of azidoepibatidine is
1994 A.K. Hamouda et al. / Biochimica et Biophysica Acta 1788 (2009) 1987–1995located at the 5 position of the chlorinated pyridine ring (Scheme 1;
[13]) and labeling of M116 in the AChBP is consistent with the crystal
structure of the epibatidine bound form of AChBP [8]. While it is not
possible to predict the precise site(s) of photoreactivity in either [125I]
epibatidine or 5[125I]A-85380, substituted pyridines, such as the
iodinated pyridine rings of both of these compounds (Fig. 5D), are
known to undergo complex photoaddition reactions [26–28]. There-
fore photoreaction of the iodinated pyridine ring for either radi-
olabeled agonist with β4Q117 is fully consistent with these published
ﬁndings.
4.2. The residue at position β2F119/β4Q117 is an important determinant
of nAChR subtype-selectivity for the agonist 5I-A-85380
Having established that β4Q117 in Loop E is the principal site of
[125I]epibatidine (and likely 5[125I]A-85380) photoinsertion, the next
question is what role does the residue at this position play in the
pharmacological properties of the nAChR. While substitutions at
β2F119Q and β2S113R had no signiﬁcant effect on the binding afﬁnity
of [3H]epibatidine to nAChRs (Fig. 5A), the β2F119Q substitution
resulted in a 4-fold reduction in the potency of 5I-A-85380 for
inhibiting the binding of [3H]epibatidine to α4β2F119Q nAChRs (Fig.
5E). These results establish that position β2F119 is important for
conferring α4β2 binding selectivity for the agonist 5I-A-85380.
However, the 4-fold shift in 5I-A-85380 inhibition potency conferred
by the β2F119Q substitution, contrasts with the nearly 200-fold
difference in potency for α4β2 vs. α4β4 nAChRs (Fig. 5E). Clearly
additional residues in Loops D and E (and perhaps elsewhere)
contribute to the receptor subtype-selectivity of 5I-A-85380 and
may in fact provide a greater contribution to selectivity than the
β2F119/β4Q117 position.
Functional studies have also contributed to our understanding of
the role of the β2F119 position. The concentration–response curves
(Fig. 7) indicate the β2F119Q mutation shifts (14-fold) the EC50 to a
higher concentration and reduces themaximal relative response to 5I-
A-85380, with no effect on the response to ACh. Such a reduction
would be expected to cause a shift of the overall relationship to higher
concentration, so the increase in EC50 might not directly reﬂect a
reduced afﬁnity for binding to the resting (closed channel) form of the
receptor. Similarly, the increase in the IC50 for inhibition of [3H]
epibatidine binding (Fig. 5E) might reﬂect either reduced afﬁnity or a
reduced ability to cause conformational changes after binding (in this
case possibly to the desensitized form of the receptor). The functional
data suggest that amajor consequence of the β2F119Qmutationmight
be a destabilization of 5I-A-85380 in the binding pocket after the
conformational changes associated with gating. In contrast, the
mutation has no signiﬁcant effect on activation by the less bulky
ACh, likely because ACh has less extensive interactions with this
region of the binding pocket on the (−) side (complementary face) of
the interface [29,30].
Finally, a very recent study has provided evidence that the high
afﬁnity of α4β2 nAChRs for ACh and nicotine (and likely for other
agonists) results from an enhanced cation–π interaction with Trp149
in Loop B [31]. Taken together, these results indicate that in general
the α4 subunit confers high-afﬁnity agonist binding but that Loop E
and in particular β2F119 is an important determinant of the receptor
subtype-selectivity of the agonist 5I-A-85380 and likely for other
agonists as well.
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